Skip to main content

Allena Pharmaceuticals, Inc. (ALNA)

NASDAQ: ALNA · Delayed Price · USD
0.682
-0.002 (-0.32%)
At close: Dec 8, 2021 4:00 PM
0.690
0.008 (1.173%)
After-hours:Dec 8, 2021 7:50 PM EST
Market Cap56.30M
Revenue (ttm)n/a
Net Income (ttm)-48.56M
Shares Out82.57M
EPS (ttm)-0.84
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume531,300
Open0.690
Previous Close0.684
Day's Range0.670 - 0.700
52-Week Range0.600 - 2.780
Beta2.08
AnalystsStrong Buy
Price Target6.13 (+799.1%)
Earnings DateNov 8, 2021

About ALNA

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients wit...

IndustryBiotechnology
IPO DateNov 2, 2017
CEOLouis Brenner
Employees35
Stock ExchangeNASDAQ
Ticker SymbolALNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ALNA stock is "Strong Buy." The 12-month stock price forecast is 6.13, which is an increase of 799.09% from the latest price.

Price Target
$6.13
(799.09% upside)
Analyst Consensus: Strong Buy

News

Allena Pharmaceuticals, Inc. (ALNA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Allena Pharmaceuticals, Inc. (ALNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisio...

2 weeks ago - Zacks Investment Research

After Plunging 19.7% in 4 Weeks, Here's Why the Trend Might Reverse for Allena Pharmaceuticals, Inc. (ALNA)

The heavy selling pressure might have exhausted for Allena Pharmaceuticals, Inc. (ALNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall...

2 weeks ago - Zacks Investment Research

Allena Pharmaceuticals (ALNA) Sees Hammer Chart Pattern: Time to Buy?

Allena Pharmaceuticals (ALNA) has been struggling lately, but the selling pressure may be coming to an end soon.

2 weeks ago - Zacks Investment Research

Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference

NEWTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and c...

3 weeks ago - GlobeNewsWire

Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress

NEWTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platfor...

4 weeks ago - GlobeNewsWire

Hot Penny Stocks to Watch as AMC and GME Go to the Moon

Which penny stocks are you watching as GME stock and AMC stock shoot toward the moon? The post Hot Penny Stocks to Watch as AMC and GME Go to the Moon appeared first on Penny Stocks to Buy, Picks, News ...

Other symbols:PTPIUEC
1 month ago - PennyStocks

Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment...

- Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract -

1 month ago - GlobeNewsWire

Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress

NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platfor...

3 months ago - GlobeNewsWire

Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

4 months ago - GlobeNewsWire

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-clas...

4 months ago - GlobeNewsWire

Allena Pharma Stock Under Pressure After Equity Raise Of $28M

Allena Pharmaceuticals Inc (NASDAQ: ALNA) has announced a registered direct offering of 21.3 million shares and warrants to purchase up to 10.7 million shares at $1.311. With gross proceeds of $28 milli...

4 months ago - Benzinga

Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

NEWTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

4 months ago - GlobeNewsWire

Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

NEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-cla...

5 months ago - GlobeNewsWire

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients w...

Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT

6 months ago - GlobeNewsWire

Top Penny Stocks For Your May Watchlist? Check These 5 Out

Looking for penny stocks to buy in May 2021? Here's some watchlist inspiration The post Top Penny Stocks For Your May Watchlist?

Other symbols:AHPIPLINRELITRIB
6 months ago - PennyStocks

Moving Average Crossover Alert: Allena Pharmaceuticals (ALNA)

Allena Pharmaceuticals (ALNA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

6 months ago - Zacks Investment Research

Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

-- Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022 -- -- Enrolling healthy volunteers in Phase 1b MAD study of ALLN-346; initial data expect...

6 months ago - GlobeNewsWire

Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors

NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

8 months ago - GlobeNewsWire

Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

-- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyper...

8 months ago - GlobeNewsWire

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March

NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzy...

9 months ago - GlobeNewsWire

7 Penny Stocks That Actually Have Buy Ratings

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

10 months ago - InvestorPlace

Allena Pharmaceuticals Appoints Richard D. Katz, M.D.

-- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -- -- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) --

10 months ago - GlobeNewsWire

Has Allena Pharmaceuticals (ALNA) Outpaced Other Medical Stocks This Year?

Is (ALNA) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

Allena Pharmaceuticals, Inc. (ALNA) Moves to Buy: Rationale Behind the Upgrade

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

10 months ago - Zacks Investment Research

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January

NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

11 months ago - GlobeNewsWire